Valuation: Roche Holding AG

Market Cap 282B 339B 302B 256B 482B 32,813B 487B 3,381B 1,323B 16,729B 1,272B 1,245B 53,538B P/E 2026 *
19x
P/E 2027 * 17.4x
Enterprise Value 293B 352B 314B 266B 501B 34,080B 506B 3,512B 1,374B 17,375B 1,322B 1,293B 55,605B EV / Sales 2026 *
4.65x
EV / Sales 2027 * 4.35x
Free-Float
88.78%
Yield 2026 *
2.84%
Yield 2027 * 2.91%

Last Transcript: Roche Holding AG

Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 345B
-1.61%+1.08%+38.64%+106.93% 1,060B
-0.76%-3.12%+35.78%+62.70% 623B
+0.39%+4.14%+17.00%+83.77% 480B
-0.29%-2.02%+62.52%+37.06% 352B
-2.03%+1.03%+22.25%+42.16% 345B
-1.92%-1.87%+11.94%+33.20% 274B
-2.36%-3.16%-6.95%+8.68% 249B
-1.37%-3.34%+37.86%+52.33% 223B
+0.17%-1.31%+25.96%+96.82% 182B
Average -1.32%-0.48%+27.22%+58.18% 420.89B
Weighted average by Cap. -0.98%+0.04%+30.57%+68.82%

Financials

2026 *2027 *
Net sales 62.91B 75.63B 67.44B 57.16B 108B 7,322B 109B 755B 295B 3,733B 284B 278B 11,947B 65.8B 79.11B 70.55B 59.79B 112B 7,660B 114B 789B 309B 3,905B 297B 291B 12,497B
Net income 14.63B 17.58B 15.68B 13.29B 25B 1,702B 25.27B 175B 68.65B 868B 66.02B 64.61B 2,778B 16.33B 19.63B 17.51B 14.84B 27.92B 1,901B 28.21B 196B 76.64B 969B 73.71B 72.13B 3,101B
Net Debt 10.88B 13.08B 11.67B 9.89B 18.61B 1,267B 18.8B 131B 51.08B 646B 49.13B 48.08B 2,067B 4.31B 5.19B 4.63B 3.92B 7.38B 502B 7.45B 51.75B 20.25B 256B 19.47B 19.06B 819B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - Roche Holding AG